Why Zimmer Biomet Holdings, Inc. (ZBH) stock moved
Zimmer Biomet Holdings, Inc. (ZBH) shares climbed 13.5% to $110.15 as of November 4, 2026, a sharp gain from the prior close of $97.06. BestStocks flagged the session as a major change for ZBH. Below, we break down what changed for ZBH, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
ZBH climbed 13.5% to $110.15
Zimmer Biomet reported third-quarter 2026 earnings and revenues that beat analyst estimates, driving shares up 12.93% to $109.61 (per Zacks and PR Newswire). The beat on both top and bottom lines triggered broad-based buying early in the session. Monitor for analyst upgrades to price targets and forward guidance commentary from the earnings call; also watch whether ZBH sustains the move above $109 through market close, as intraday data is delayed.
What it means for Zimmer Biomet Holdings, Inc. investors
For Zimmer Biomet Holdings, Inc. investors, the balance of recent signals points to a bullish shift. On the constructive side: Material positive event; Strong 13.5% price move with conviction. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $104.14, implying -5.5% downside from $110.15. BestStocks rates the overall signal quality medium (74/100). With earnings roughly 97 days out, the next report is the most likely near-term test of the move.
ZBH price reaction
ZBH last traded at $110.15, up $13.09 (+13.49%) from the previous close of $97.06. The session traded on 2.8× average volume (very high), so the move carried above-average conviction.
Bullish and bearish analyst opinions on Zimmer Biomet Holdings, Inc. (ZBH)
The consensus analyst price target on Zimmer Biomet Holdings, Inc. (ZBH) is $104.14, 5.5% below the recent $110.15. Over the past 90 days analysts logged 0 upgrades, 6 maintains, and 0 downgrades. Here is how the bullish and bearish cases on ZBH line up.
The bullish case
- The Street's most bullish target is $120.00 (+8.9%).
- Material positive event.
- Strong 13.5% price move with conviction.
- Volume 2.8x average — institutional conviction.
- Zimmer Biomet reported third-quarter 2026 earnings and revenues that beat analyst estimates, driving shares up 12.93% to $109.61 (per Zacks and PR Newswire).
The bearish case
- The consensus analyst price target of $104.14 sits 5.5% below the recent $110.15, so the average target sees limited room to run.
- The most bearish analyst target is $93.00 (-15.6%).
Weighing both sides, BestStocks' composite read of recent signals is bullish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 4, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for ZBH
Frequently asked questions about ZBH
Why did Zimmer Biomet Holdings, Inc. (ZBH) stock move?
ZBH climbed 13.5% to $110.15. The move coincided with the context summarized above, though no single company-specific catalyst was independently confirmed.
How much did ZBH stock rise?
ZBH gained 13.49% ($13.09) versus the prior close of $97.06, last trading at $110.15 on 2.8× average volume.
When is Zimmer Biomet Holdings, Inc.'s next earnings date?
ZBH's next earnings report is estimated for 2027-02-09 — about 97 days away.
What is the analyst price target for ZBH?
The consensus analyst price target for ZBH is $104.14, about 5.5% below the current $110.15. Over the past 90 days, analysts recorded 0 upgrades, 6 maintains, and 0 downgrades.
How BestStocks tracks ZBH
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared ZBH-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for ZBH, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 4, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.